Amgen

Open: 224.85 Close: 223.99 Change: -0.86

The unbelievably easy way to evaluate Amgen: Use an AI.

Are looking for the most relevant information about Amgen? Investor spend a lot of time searching for information to make investment decisions in Amgen. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, block, acquisition, Horizon, FTC, Therapeutics, Federal, and the most common words in the summary are: amgen, horizon, ftc, best, stock, drug, deal, . One of the sentences in the summary was: to use rebates on its existing drugs to pressure bill payers into favoring Tepezz …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Federal Trade Commission said the deal would enable Amgen to exploit its size to block competition. FTC said deal would allow Amgen. to use rebates on its existing drugs to pressure bill payers into favoring Tepezz and Krystexxa.

Today's News

U.S. sues to block amgens $27.8 billion takeover of horizon therapeutics - The New York Times. Federal Trade Commission said the deal would enable Amgen to exploit its size to block competition. Amgen stock price ended down by more than 2% on Tuesday. Federal Trade Commission filed a lawsuit seeking to block drug giant Amgen s $27.8 billion acquisition. Amgen agrees not to seek quick close to Horizon Therapeutics acquisition. Justices rule unanimously that Amgen patents relating to its cholesterol drug Repatha shouldnt have been granted. Sanofi wins supreme court patent dispute with amgen. Federal regulators are suing to block biotech drug developer Amgens more than $26 billion deal for Horizon Therapeutics. FTC said Tuesday that the deal would give Amgen unfair leverage to block competition. The Supreme Court concluded that “Amgen offers persons skilled in the art little more than advice to engage in ‘trial and error” The expert testified that the specification and supporting information. Federal Trade Commission sues to block biopharmaceutical giant Amgen from acquisition that would entrench monopoly drugs used to treat two serious illnesses. $27.8 billion acquisition of Horizon Therapeutics plc would enable Amgen Inc. to stifle competition. U.S. Supreme Court rules against Amgen bid to revive cholesterol-lowering drug Repatha patents. FTC faces uphill battle in its fight to block Amgens $27.8 billion acquisition of Horizon Therapeutics. Mizuho healthcare sector strategist Jared Holz joins Fast Money to discuss merger and acquisition crackdown. Federal Trade Commission sues to block Amgen acquisition of Horizon Therapeutics. FTC is preparing to seek an injunction in federal court that would prevent the deal from closing. Amgen reported an EPS of $3.98 in its last earnings report, beating expectations. Among the largest hedge funds holding Amgens share is PRIMECAP Management Co. It holds shares valued at 4B. Federal Trade Commission (FTC) is expected to introduce a lawsuit to block the proposed $27.8 billion merger with Amgen (NASDAQ:AMGN) New Relics potential $5B acquisition at Magellan Midstream/Oneok and Urstadt Biddle/Regency Centers. Federal Trade Commission filed a lawsuit to stop Amgen Inc. from buying Horizon Therapeutics Plc for $27.8 billion. FTC Bureau of Competition Director Holly Vedova said: Rampant consolidation in the pharmaceutical industry has given powerful companies a pass to exorbitantly hike prescription drug prices Federal Trade Commission sues to block Amgen’s $27.8 billion acquisition of Horizon Therapeutics. Amgen said it is disappointed by the FTCs decision and remains committed to completing this acquisition FTC sues to block Amgens $26 billion acquisition of Horizon Therapeutics. FTC said deal would give Amgen unfair leverage to block competition for Horizon medications. FTC: Deal would allow Amgen to use rebates on its existing drugs to pressure bill payers. FTC sues to block Amgens $27.8 billion acquisition of Horizon Therapeutics. FTC said deal would allow Amgen to use rebates on its existing drugs to pressure bill payers into favoring Tepezz and Krystexxa.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

The game is changing. There is a new strategy to evaluate Amgen fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, block, acquisition, Horizon, FTC, Therapeutics, Federal, and the most common words in the summary are: amgen, horizon, ftc, best, stock, drug, deal, . One of the sentences in the summary was: to use rebates on its existing drugs to pressure bill payers into favoring Tepezz and Krystexxa.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #horizon #ftc #best #stock #drug #deal.